ESMO Breast 2022 | KEYNOTE-355: HRQoL unaffected by the addition of pembrolizumab to chemotherapy for TNBC

Dave Cescon, MD, PhD, Princess Margaret Cancer Centre, Toronto, Canada, talks on the Phase III KEYNOTE-355 trial (NCT02819518), focusing on patients reported outcomes (PRO) and health-related quality of life (HRQoL). Previously, the KEYNOTE-355 trial demonstrated an improved overall-survival (OS) and progression-free survival (PFS) resulting in the approval of chemotherapy plus pembrolizumab for patients with locally recurrent unresectable or metastatic triple-negative breast cancer (TNBC) and a Combined Positive Score (CPS) of ≥ 10. PRO and HRQoL were secondary and exploratory outcomes. There was no evidence of a decrease in HRQoL with the addition of pembrolizumab to chemotherapy. This interview took place at the European Society for Medical Oncology (ESMO) Breast Cancer 2022 congress in Berlin, Germany.